Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
J Biol Chem 277:2694426949 Couturier J, Przybyla-Toscano J, Roret T, Didierjean C, Rouhier N (2015) The roles of glutaredoxins ligating Fe-S clusters: sensing, transfer or repair functions
Magness, currently coach at the University of Houston, was joined by marathoner and world championship medalist Kara Goucher as the main whistleblowers in the 2015 report
Weight changes are determined by diet, exercise, metabolism, and hormonal balance, not by glutathione supplementation
Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor
If your diet is not allowing you to get enough of the B12 vitamin then a regular B12 injection regimen may be right for you